BioSpectrum
the business of Bi
24 years of leveraging the business of Bio
www.biospectrumindia.co

Neuberg Centre for Genomic Medicine revolutionises prenatal diagnosis outcomes

08 March 2023 | News

With an aim to providing better sensitivity, better detection and expanding scope and coverage with better technology



Neuberg Centre for Genomic Medicine (NCGM) has announced the launch of the most cutting edge and fastest prenatal diagnostic test called the Prenatal Aneuploidy NCG test (PAN Test) and an upgraded version of Chromosomal Microarray Analysis test with launch of Cyto-ONE test for the first time in India.

Neuberg's PAN test and Cyto-ONE test are innovative prenatal diagnostic tests that are designed to provide better coverage of disorders in the foetus without compromising on turnaround time or cost. These tests are developed by Neuberg Centre for Genomic Medicine, and they represent significant upgrades to existing technologies for diagnosing foetal abnormalities.

The PAN test is capable of detecting abnormalities on all chromosomes and sub-chromosomal regions, providing comprehensive answers for doctors and expecting mothers who wish to get most robust and exhaustive diagnostic results in the shortest time without the need for getting multiple tests done.

The Cyto-One test is a high resolution microarray based test that will transform the realm of definitive diagnosis. This test is a major upgrade to the currently available microarray tests with its over 1 million probes, higher detection rates and lower failure rates. It will help doctors get better quality diagnostic results in both- prenatal and postnatal settings.

The advantage is that the new PAN test has better sensitivity and detection capabilities than the current QF-PCR test. It can detect more disorders and covers 22 chromosomal instead of just 5, which expands its scope and coverage. The test has a quick turnaround time of 48-72 hours and at no additional cost, making it more accessible to doctors and patients.